91 related articles for article (PubMed ID: 9706913)
21. The application of tranexamic acid in joint arthroplasty: A 20-year bibliometric analysis.
Zhang J; Zhao R; Huang Y; Xiong C; Liang H; Jiwa H; Luo X
Front Public Health; 2022; 10():1013461. PubMed ID: 36388346
[TBL] [Abstract][Full Text] [Related]
22. Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review.
Ockerman A; Vanassche T; Garip M; Vandenbriele C; Engelen MM; Martens J; Politis C; Jacobs R; Verhamme P
Thromb J; 2021 Aug; 19(1):54. PubMed ID: 34380507
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the use of tranexamic acid in total knee arthroplasty.
Almeida MDC; Albuquerque RPE; Palhares GM; Almeida JPC; Barretto JM; Cavanellas N
Rev Bras Ortop; 2018; 53(6):761-767. PubMed ID: 30377612
[TBL] [Abstract][Full Text] [Related]
24. Topical vs. intravenous administration of tranexamic acid in knee arthroplasty and prevalence of deep venous thrombosis: a randomized clinical trial.
Zekcer A; Del Priori R; Tieppo C; da Silva RS; Severino NR
J Vasc Bras; 2016; 15(2):120-125. PubMed ID: 29930576
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of topical
Zekcer A; Priori RD; Tieppo C; Silva RSD; Severino NR
Rev Bras Ortop; 2017; 52(5):589-595. PubMed ID: 29062824
[TBL] [Abstract][Full Text] [Related]
26. Clinical and instrumental evaluation of two different regimens of tranexamic acid in total hip arthroplasty: a single-centre, prospective, randomized study with 80 patients.
Piolanti N; Del Chiaro A; Matassi F; Graceffa A; Nistri L; Marcucci M
Eur J Orthop Surg Traumatol; 2018 Feb; 28(2):233-237. PubMed ID: 28887640
[TBL] [Abstract][Full Text] [Related]
27. The prophylactic role of tranexamic acid to reduce blood loss during radical surgery: A prospective study.
Gupta K; Rastogi B; Krishan A; Gupta A; Singh VP; Agarwal S
Anesth Essays Res; 2012; 6(1):70-3. PubMed ID: 25885506
[TBL] [Abstract][Full Text] [Related]
28. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid -- a meta-analysis of randomised and observational trials of over 30.000 patients.
Meybohm P; Herrmann E; Nierhoff J; Zacharowski K
PLoS One; 2013; 8(3):e58009. PubMed ID: 23483965
[TBL] [Abstract][Full Text] [Related]
29. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients.
Maniar RN; Kumar G; Singhi T; Nayak RM; Maniar PR
Clin Orthop Relat Res; 2012 Sep; 470(9):2605-12. PubMed ID: 22419350
[TBL] [Abstract][Full Text] [Related]
30. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Henry DA; Carless PA; Moxey AJ; O'Connell D; Stokes BJ; Fergusson DA; Ker K
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD001886. PubMed ID: 21412876
[TBL] [Abstract][Full Text] [Related]
31. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.
Carless PA; Moxey AJ; Stokes BJ; Henry DA
BMC Cardiovasc Disord; 2005 Jul; 5():19. PubMed ID: 15992412
[TBL] [Abstract][Full Text] [Related]
32. Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.
Yamasaki S; Masuhara K; Fuji T
Int Orthop; 2004 Apr; 28(2):69-73. PubMed ID: 15224162
[TBL] [Abstract][Full Text] [Related]
33. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial.
Brown RS; Thwaites BK; Mongan PD
Anesth Analg; 1997 Nov; 85(5):963-70. PubMed ID: 9356085
[TBL] [Abstract][Full Text] [Related]
34. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
35. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial.
Hekmat K; Zimmermann T; Kampe S; Kasper SM; Weber HJ; Geissler HJ; Mehlhorn U
Curr Med Res Opin; 2004 Jan; 20(1):121-6. PubMed ID: 14741082
[TBL] [Abstract][Full Text] [Related]
36. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.
Menkis AH; Martin J; Cheng DC; Fitzgerald DC; Freedman JJ; Gao C; Koster A; Mackenzie GS; Murphy GJ; Spiess B; Ad N
Innovations (Phila); 2012; 7(4):229-41. PubMed ID: 23123988
[TBL] [Abstract][Full Text] [Related]
37. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.
Peters DC; Noble S
Drugs; 1999 Feb; 57(2):233-60. PubMed ID: 10188764
[TBL] [Abstract][Full Text] [Related]
38. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization.
Mongan PD; Brown RS; Thwaites BK
Anesth Analg; 1998 Aug; 87(2):258-65. PubMed ID: 9706913
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
